Search Results - "Scott Chandler, G"

Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade by Khan, Zia, Hammer, Christian, Carroll, Jonathan, Di Nucci, Flavia, Acosta, Sergio Ley, Maiya, Vidya, Bhangale, Tushar, Hunkapiller, Julie, Mellman, Ira, Albert, Matthew L., McCarthy, Mark I., Chandler, G. Scott

“…Activation of systemic immune responses using PD-1 checkpoint inhibitors is an essential approach to cancer therapy. Yet, the extent of benefit relative to…”
Get full text

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer by Khan, Zia, Di Nucci, Flavia, Kwan, Antonia, Hammer, Christian, Mariathasan, Sanjeev, Rouilly, Vincent, Carroll, Jonathan, Fontes, Magnus, Acosta, Sergio Ley, Guardino, Ellie, Chen-Harris, Haiyin, Bhangale, Tushar, Mellman, Ira, Rosenberg, Jonathan, Powles, Thomas, Hunkapiller, Julie, Chandler, G. Scott, Albert, Matthew L.

“…PD-1 and PD-L1 act to restrict T cell responses in cancer and contribute to self-tolerance. Consistent with this role, PD-1 checkpoint inhibitors have been…”
Get full text

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach by Khan, Zia, Hammer, Christian, Guardino, Ellie, Chandler, G Scott, Albert, Matthew L

“…Personalized care of cancer patients undergoing treatment with immune checkpoint inhibitors will require approaches that can predict their susceptibility to…”
Get full text

Baseline risk factors associated with immune related adverse events and atezolizumab by Madjar, Katrin, Mohindra, Rajat, Durán-Pacheco, Gonzalo, Rasul, Rashad, Essioux, Laurent, Maiya, Vidya, Chandler, G Scott

“…Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer patients in the last decade, but immune-related adverse events (irAEs) pose…”
Get full text

Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy by Khan, Zia, Jung, Min, Crow, Megan, Mohindra, Rajat, Maiya, Vidya, Kaminker, Joshua S, Hackos, David H, Chandler, G Scott, McCarthy, Mark I, Bhangale, Tushar

“…Dose-limiting toxicities significantly impact the benefit/risk profile of many drugs. Whole genome sequencing (WGS) in patients receiving drugs with…”
Get full text

449 Polygenic risk scores for liver injury are associated with the risk for autoimmune hepatitis in patients treated with atezolizumab by Saha, Ashis, Adams, Cameron, Roe, David, McCarthy, Mark, Mellman, Ira, Mohindra, Rajat, Scott Chandler, G, Hammer, Christian

“…BackgroundImmune checkpoint inhibitor (ICI)-induced hepatitis is a relatively common immune-related adverse event (irAE).1–3 Understanding the underlying…”
Get full text

445 The relationship between immune-related adverse events (irAEs) and ctDNA status: exploratory analysis from IMvigor010 by Carter, Corey, Madjar, Katrin, Balas, Bogdana I, Essioux, Laurent, Degaonkar, Viraj, Mariathasan, Sanjeev, Scott Chandler, G, Mohindra, Rajat, Powles, Thomas

“…BackgroundIMvigor010 (NCT02450331) showed that atezolizumab reduced risk of death by approximately 40% in post-cystectomy ctDNA-positive patients.1 Whether…”
Get full text

811 Allelic variation in Human Leukocyte Antigen class II genes is associated with pneumonitis risk in cancer patients treated with immune checkpoint inhibitors by Saha, Ashis, Spencer, Christine, Khan, Zia, Carroll, Jonathan, Arellano, Claudia Yanez, Hunkapiller, Julie, Bayless, Nicholas, Nissola, Leonardo, Wallace, Roslyn, Mellman, Ira, Mohindra, Rajat, Bucktrout, Samantha, Sandhu, Shahneen, Scott Chandler, G., Hammer, Christian

“…BackgroundImmune-mediated adverse events (imAE) commonly occur in patients treated with immune checkpoint inhibitors (ICI), and pneumonitis is known to occur…”
Get full text

Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures by Kao, Chester J, Charmsaz, Soren, Alden, Stephanie L, Brancati, Madelena, Li, Howard L, Balaji, Aanika, Munjal, Kabeer, Howe, Kathryn, Mitchell, Sarah, Leatherman, James, Griffin, Ervin, Nakazawa, Mari, Tsai, Hua-Ling, Danilova, Ludmila, Thoburn, Chris, Gizzi, Jennifer, Gross, Nicole E, Hernandez, Alexei, Coyne, Erin M, Shin, Sarah M, Babu, Jayalaxmi Suresh, Apostol, George W, Durham, Jennifer, Christmas, Brian J, Konig, Maximilian F, Lipson, Evan J, Naidoo, Jarushka, Cappelli, Laura C, Pabani, Aliyah, Ged, Yasser, Baretti, Marina, Brahmer, Julie, Hoffman-Censits, Jean, Seiwert, Tanguy Y, Garonce-Hediger, Rachel, Guha, Aditi, Bansal, Sanjay, Tang, Laura, Jaffee, Elizabeth M, Chandler, G Scott, Mohindra, Rajat, Ho, Won Jin, Yarchoan, Mark

“…BACKGROUNDImmune-related adverse events (irAEs) and their associated morbidity/mortality are a key concern for patients receiving immune checkpoint inhibitors…”
Get full text

Correlation of safety and efficacy of atezolizumab therapy across indications by Durán-Pacheco, Gonzalo, Chandler, G Scott, Maiya, Vidya, Socinski, Mark A, Sonpavde, Guru, Puente, Javier, Essioux, Laurent, Carter, Corey, Cardona, Jose Vicente, Mohindra, Rajat, Naidoo, Jarushka

“…The association between safety and efficacy of immune checkpoint inhibitors is known, but the correlation between severity and impact of specific organ…”
Get full text

Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language Processing by Barman, Hannah, Venkateswaran, Sriram, Santo, Antonio Del, Yoo, Unice, Silvert, Eli, Rao, Krishna, Raghunathan, Bharathwaj, Kottschade, Lisa A, Block, Matthew S, Chandler, G Scott, Zalis, Joshua, Wagner, Tyler E, Mohindra, Rajat

“…Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their use is associated with immune-related adverse events (irAEs). Estimating…”
Get more information

1245 Th17 and Type 2 CD8+ cytokine signatures predict irAEs in solid tumors by Kao, Chester J, Charmsaz, Soren, Brancati, Madalena, Alden, Stephanie L, Li, Howard L, Balaji, Aanika, Munjal, Kabeer, Tsai, Hua-Ling, Danilova, Ludmila, Hernandez, Alexei, Gross, Nicole, Coyne, Erin M, Shin, Sarah M, Durham, Jennifer, Christmas, Brian, Thoburn, Christopher, Konig, Maximilian F, Lipson, Evan J, Naidoo, Jarushka, Cappelli, Laura, Ged, Yasser, Barretti, Marina, Brahmer, Julie, Hoffman-Censits, Jean, Seiwert, Tanguy Y, Garonce-Hediger, Rachel, Bansal, Sanjay, Tang, Laura, Jaffee, Elizabeth M, Scott Chandler, G, Mohindra, Rajat, Ho, Won Jin, Yarchoan, Mark

“…BackgroundImmune related adverse events (irAEs) and their associated morbidity/mortality are a key concern for patients receiving immune checkpoint inhibitors…”
Get full text

Antibody profiling of COVID-19 patients reveals antibodies and autoantibodies that may be associated with faster recovery from COVID-19 by Onabajo, Olusegun, Budde, Petra, Kuebler, Peter, Bräutigam, Manuel, Haridha, Shivram, Stubbings, William, Tsai, Larry, Zucht, Hans-Dieter, Chandler, G. Scott, McBride, Jacqueline, Bauer, Rebecca

“…COVID-19 infection exhibits a broad spectrum of clinical outcomes and a combination of host and viral factors interact to drive variability in COVID-19…”
Get full text

Cytokine Release Syndrome: The Patient, Caregiver and Healthcare Professional Experience by Soong, Janelle, De Carlo, Giuseppe, Lasi-Tejani, Naziah, Sethi, Sumanjit K., Bolaños, Natacha, Elias, Martine, Biru, Yelak, Clavreul, Solène, Chandler, G. Scott, Finzler, Klaus, Nouet, Yann, Del Santo, Antonio Giuseppe

“…Background: Cytokine release syndrome (CRS) is a supraphysiologic response to T-cell engaging immunotherapy that can negatively impact the treatment experience…”
Get full text

Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population by Balaji, Aanika, Alden, Stephanie Leigh, Li, Howard, Munjal, Kabeer, Lipson, Evan J., Naidoo, Jarushka, Cappelli, Laura, Ged, Yasser, Hoffman-Censits, Jean H., Mohindra, Rajat, Garonce-Hediger, Rachel, Seiwert, Tanguy Y., Bansal, Sanjay, Tang, Laura, Chandler, G Scott, Yarchoan, Mark, Kao, Chester

“…2662 Background: IrAEs associated with immune checkpoint inhibitors (ICIs) can result in morbidity and mortality. The incidence, spectrum, and risk factors for…”
Get full text

Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study by Rodriguez-Abreu, Delvys, Budde, Petra Ilse, Zucht, Hans-Dieter, Shrivastava, Divya, Kilian, Annika Loredana, Höglander, Elen, Shoshkova, Stefaniya, Markovic, Marija, Kaul, Monika Dulloo, Cardona, Jose Vicente, Chandler, G Scott, Mohindra, Rajat

“…2512 Background: Patients (pts) with pre-existing autoimmune diseases (AID) and prior immune checkpoint inhibitor (ICI) experience were historically excluded…”
Get full text

Patient-derived skin MicroOrganoSpheres and clinical response to immunotherapy by Chakraborty, Rikhia, Fagan-Solis, Katerina, DeVilla, Jessica, Recaldin, Timothy, Bscheider, Michael, Gjorevski, Nikolche, Fullerton, Aaron, Prell, Rodney, Khan, Zia, Wang, Zhaohui, Ding, Shengli, Glass, Carolyn, Jeck, William, McCall, Shannon J., Beasley, Georgia, Mohindra, Rajat, Hsu, Shiaowen David, Chandler, G Scott, Shen, Xiling, Roth, Adrian B

“…2588 Background: Immunotherapies, including immune checkpoint inhibitors (ICI), have revolutionized the treatment of many cancers, producing significant…”
Get full text

The role of natural language processing techniques versus conventional methods to gain ICI safety insights from unstructured EHR data by Block, Matthew Stephen, Barman, Hannah, Venkateswaran, Sriram, Del Santo, Antonio Giuseppe, Yoo, Unice, Silvert, Eli, Chandler, G Scott, Wagner, Tyler, Mohindra, Rajat

“…136 Background: Studies using International Classification of Diseases (ICD) codes have aimed to characterize the safety profile of cancer therapies in the…”
Get full text

Abstract 3846: The obesity paradox in immune checkpoint blockade: A pan-tumor analysis by Alden, Stephanie Leigh, Charmsaz, Soren, Brancati, Madelena, Li, Howard L., Warner, Aanika, Munjal, Kabeer, Howe, Kathryn, Mitchell, Sarah, Griffin, Ervin, Nakazawa, Mari, Tsai, Hua-Ling, Danilova, Ludmila, Thoburn, Chris, Gizzi, Jennifer, Hernandez, Alexei, Gross, Nicole E., Coyne, Erin M., Shin, Sarah M., Durham, Jennifer, Konig, Maximilian F., Christmas, Brian J., Lipson, Evan J., Naidoo, Jarushka, Cappelli, Laura C., Pabani, Aliyah, Ged, Yasser, Baretti, Marina, Brahmer, Julie R., Hoffman-Censits, Jean, Seiwert, Tanguy Y., Bansal, Sanjay, Tang, Laura, Jaffee, Elizabeth, Chandler, G Scott, Mohindra, Rajat, Ho, Won Jin, Yarchoan, Mark, Kao, Chester

“…Background: Chronic systemic inflammation mediated by pro-inflammatory cytokines serves as a major mechanism by which obesity contributes to cancer…”
Get full text

Phase Ib study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab (bev) with or without paclitaxel by Goldman, Jonathan Wade, Gordon, Michael S., Munster, Pamela N., Bergsland, Emily K., Moore, Amy Patricia, Bai, Shuang, Hegde, Priti, Fredrickson, Jill O., Chang, Ilsung, Chandler, G. Scott, Funke, Roel Peter, Rhee, Ina Park, Chen, Daniel S., Rosen, Lee S.

“…Abstract only e13000 Background: Epidermal growth factor-like domain 7 (EGFL7), is a vascular-restricted, tumor selective, extracellular matrix protein that…”
Get full text